Clinical Investigator and Nursing Perspectives on the Management of Common Cancers

FACULTY INTERVIEWS
Axel Grothey, MD
Jessica Mitchell, RN, CNP, MPH

EDITOR
Neil Love, MD
Cancer of the colon and rectum is one of the most rapidly evolving fields in oncology nursing and is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in the United States (approximately 9% of all cancer deaths). Published results from ongoing trials continually lead to the emergence of novel biomarkers and new therapeutic targets and regimens, so that individualized therapeutic approaches have become the standard. This paradigm shift presents a challenge to practicing oncologists and other members of the treatment team who must grapple with the presentation of ambiguous data sets and their immediate implications for management decisions. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with metastatic colorectal cancer (mCRC), the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with mCRC. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with mCRC.

PURPOSE STATEMENT
To present the most current research developments in mCRC and to provide the perspectives of a medical oncologist and oncology nurse on the treatment of mCRC.

LEARNING OBJECTIVES
• Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of mCRC, including chemotherapy and targeted biologic approaches.
• Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
• Recognize the recent FDA approvals of bevacizumab upon disease progression, aflibercept and regorafenib, and identify clinical situations for which these agents may be appropriate therapeutic options.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with mCRC.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.4 contact hours is provided by Research To Practice during the period of March 2014 through March 2015.

FOR SUCCESSFUL COMPLETION
This is an audio CNE program. This booklet contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website ResearchToPractice.com/ONUCRC114 also includes links to relevant abstracts and full-text articles.

To receive credit, participants should read the learning objectives and faculty disclosures, listen to the CD and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/ONUCRC114/CNE. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 75% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Regeneron Pharmaceuticals and Sanofi.

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

If you would like to discontinue your complimentary subscription to Oncology Nursing Update, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.
CNE INFORMATION

FACULTY AFFILIATIONS

Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Jessica Mitchell, RN, CNP, MPH
Certified Nurse Practitioner
GI Medical Oncology
Mayo Clinic
Rochester, Minnesota

EDITOR

Neil Love, MD
Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Grothey — Contracted Research: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Lilly. Ms Mitchell — Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals.


RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
SELECT PUBLICATIONS


Arnold D et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). Proc ASCO 2012; Abstract CRA3503.


Grothey A et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Gastrointestinal Cancers Symposium 2012; Abstract LBA385.


QUESTIONS (PLEASE CIRCLE ANSWER):

1. Which of the following is an FDA-approved option for continued anti-angiogenic, VEGF-targeted treatment after disease progression on first-line therapy for mCRC?
   a. Aflibercept
   b. Bevacizumab beyond progression
   c. Cetuximab
   d. Both a and b
   e. All of the above

2. Common side effects associated with aflibercept include ____________.
   a. Hypertension
   b. Neutropenia
   c. Diarrhea
   d. All of the above

3. Patients with ____________ do not benefit from treatment with EGFR antibodies (cetuximab, panitumumab).
   a. KRAS mutation-positive mCRC
   b. KRAS wild-type mCRC

4. Potential contraindications to the use of bevacizumab include ____________.
   a. Recent myocardial infarction
   b. Recent stroke
   c. Presence of a colon stent
   d. All of the above

5. Regorafenib is an orally administered ____________.
   a. EGFR antibody
   b. Multikinase inhibitor
   c. Immunotherapeutic agent

6. On the STEPP study, which evaluated preemptive versus reactive treatment for skin toxicities associated with the use of panitumumab, preemptive skin treatment consisting of ____________ resulted in decreased dermatologic toxicities.
   a. Skin moisturizing lotions
   b. Sunscreen applied before going outdoors
   c. Topical steroid cream applied twice a day
   d. Doxycycline antibiotic
   e. All of the above

7. The Phase III CORRECT trial of regorafenib in combination with best supportive care versus placebo in combination with best supportive care for patients with mCRC whose disease progressed on standard therapies reported a statistically significant improvement in median overall survival for patients who received regorafenib.
   a. True
   b. False

8. ____________ is a side effect commonly associated with regorafenib therapy for patients with mCRC.
   a. Hand-foot skin reaction
   b. Hypertension
   c. Diarrhea
   d. Fatigue
   e. All of the above
EDUCATIONAL ASSESSMENT AND CREDIT FORM

Oncology Nursing Update Metastatic Colorectal Cancer — Issue 1, 2014

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

<table>
<thead>
<tr>
<th>4 = Excellent</th>
<th>3 = Good</th>
<th>2 = Adequate</th>
<th>1 = Suboptimal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BEFORE</td>
<td>AFTER</td>
<td></td>
</tr>
</tbody>
</table>

- Results of the CORRECT trial of regorafenib with best supportive care (BSC) versus placebo with BSC for patients with mCRC whose disease has progressed after standard therapies
- Management of bevacizumab-associated hypertension
- Prophylaxis of dermatologic toxicities associated with EGFR antibodies
- New options for continued anti-angiogenic treatment — aflibercept, bevacizumab beyond progression, regorafenib — after disease progression on first-line therapy for mCRC
- Prevention and management of regorafenib-related hand-foot syndrome

Has the activity unfairly influenced you toward a particular product or service?
- ☐ Yes
- ☐ No

If yes, please describe what was presented:

Will this activity help you improve patient care?
- ☐ Yes
- ☐ No
- ☐ Not applicable

If yes, how will it help you improve patient care?

Did the activity meet your educational needs and expectations?
- ☐ Yes
- ☐ No

If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

<table>
<thead>
<tr>
<th>4 = Yes</th>
<th>3 = Will consider</th>
<th>2 = No</th>
<th>1 = Already doing</th>
<th>N/M = LO not met</th>
<th>N/A = Not applicable</th>
</tr>
</thead>
</table>

As a result of this activity, I will be able to:

- Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of mCRC, including chemotherapy and targeted biologic approaches. 4 3 2 1 N/M N/A
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment. 4 3 2 1 N/M N/A
- Recognize the recent FDA approvals of bevacizumab upon disease progression, aflibercept and regorafenib, and identify clinical situations for which these agents may be appropriate therapeutic options. 4 3 2 1 N/M N/A
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with mCRC. 4 3 2 1 N/M N/A
What other practice changes will you make or consider making as a result of this activity?

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

☐ Yes, I am willing to participate in a follow-up survey.
☐ No, I am not willing to participate in a follow-up survey.

PART 2 — Please tell us about the faculty and editor for this educational activity

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axel Grothey, MD</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Jessica Mitchell, RN, CNP, MPH</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Editor</td>
<td>Knowledge of subject matter</td>
<td>Effectiveness as an educator</td>
</tr>
<tr>
<td>Neil Love, MD</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

Please recommend additional faculty for future activities:

Other comments about the faculty and editor for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: ................................................. Specialty: .................................................

Professional Designation:
☐ MD  ☐ DO  ☐ PharmD  ☐ NP  ☐ CNS  ☐ RN  ☐ PA  ☐ Other

Street Address: ................................................. Box/Suite: .................................................

City, State, Zip: ................................................. Telegraph: .................................................

Telephone: ................................................. Fax: .................................................

Email: .................................................

Signature: ................................................. Date: .................................................

The expiration date for this activity is March 2015. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/ONUCRC114/CNE.
The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.